ArticleLa Radiologia medica2024
CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn's disease.
Article in La Radiologia medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- CT‑based radiomics of bowel wall at baseline predicts the efficacy of Ustekinumab at week 16 in patients with Crohn's disease.Abdominal radiology (New York) · 2026Article
- Crohn's disease: research progress in decoding pathogenic multi-network and precision management of artificial intelligence radiomics.Frontiers in immunology · 2026Review
- Imbalance between skeletal muscle and intermuscular fat predicts treatment failure in Crohn's disease: an imaging biomarker for risk stratification.Annals of medicine · 2025Article
- Expanding the role of radiomics and artificial intelligence in the management of inflammatory bowel disease: Insights, opportunities, and challenges.World journal of gastroenterology · 2025Article
- Novel endoluminal parameters for predicting primary loss of response in Crohn's disease: a multi-center study.Insights into imaging · 2025Article
- CT-based delta-radiomics signature of visceral adipose tissue for prediction of disease progression in ileal stricturing Crohn's disease.Japanese journal of radiology · 2025Article
- Creeping fat: A promising radiological predictor in small bowel Crohn's disease.World journal of gastroenterology · 2025Article
- Radiomics nomogram based on dual-energy CT-derived iodine maps: evaluation of mucosal healing in patients with Crohn's disease.Abdominal radiology (New York) · 2025Article
- A study on the prediction of targeted therapy efficacy in advanced lung adenocarcinoma patients with EGFR mutations using CT-based delta-radiomics model.Frontiers in medicine · 2025Article
- Prediction of early mucosal healing of Crohn's disease after treatment with biologics- a novel nomogram based on radiomics and clinical risk factors.Frontiers in pharmacology · 2025Article
- An Informative Review of Radiomics Studies on Cancer Imaging: The Main Findings, Challenges and Limitations of the Methodologies.Current oncology (Toronto, Ont.) · 2024Review
- Deep-Learning, Radiomics and Clinic Based Fusion Models for Predicting Response to Infliximab in Crohn's Disease Patients: A Multicentre, Retrospective Study.Journal of inflammation research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeAccurately predicting the treatment response in patients with Crohn's disease (CD) receiving infliximab therapy is crucial for clinical decision-making. We aimed to construct a prediction model incorporating radiomics and body composition features derived from computed tomography (CT) enterography for identifying individuals at high risk for infliximab treatment failure.
methodsThis retrospective study included 137 patients with CD between 2015 and 2021, who were divided into a training cohort and a validation cohort with a ratio of 7:3. Patients underwent CT enterography examinations within 1 month before infliximab initiation. Radiomic features of the intestinal segments involved were extracted, and body composition features were measured at the level of the L3 lumbar vertebra. A model that combined radiomics with body composition was constructed. The primary outcome was the occurrence of infliximab treatment failure within 1 year. The model performance was evaluated using discrimination, calibration, and decision curves.
resultsFifty-two patients (38.0%) showed infliximab treatment failure. Eight significant radiomic features were used to develop the radiomics model. The model incorporating radiomics model score, skeletal muscle index (SMI), and creeping fat showed good discrimination for predicting infliximab treatment failure, with an area under the curve (AUC) of 0.88 (95% CI 0.81, 0.95) in the training cohort and 0.83 (95% CI 0.66, 1.00) in the validation cohort. The favorable clinical application was observed using decision curve analysis.
conclusionsWe constructed a comprehensive model incorporating radiomics and muscle volume, which could potentially be used to facilitate the individualized prediction of infliximab treatment response in patients with CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.